A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

Clinical trial NCT07157254 · RECRUITING

Trial details

NCT number: NCT07157254
Sponsor: Ultragenyx Pharmaceutical Inc
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Angelman Syndrome

Start date: 2025-10-13
Primary completion: 2030-01-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.